{
    "score": [
        0.8333333333333334
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "comparing bio-rad laboratories and surmodics ."
    ],
    "id": "642309.train",
    "article": [
        "bio-rad laboratories and surmodics are both medical companies , but which is the superior stock ? we will compare the two companies based on the strength of their risk , institutional ownership , valuation , profitability , dividends , earnings and analyst recommendations . insider and institutional ownership63 .9 % of bio-rad laboratories shares are owned by institutional investors . comparatively , 85.6 % of surmodics shares are owned by institutional investors . 28.3 % of bio-rad laboratories shares are owned by insiders . comparatively , 6.4 % of surmodics shares are owned by insiders . strong institutional ownership is an indication that hedge funds , large money managers and endowments believe a stock will outperform the market over the long term . ",
        "earnings and valuationthis table compares bio-rad laboratories and surmodics ' revenue , earnings per share and valuation . gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratiobio-rad laboratories $ 2.07 billion3 .60 $ 28.12 million $ 0.79317.05 surmodics $ 73.11 million5 .05 $ 3.92 million $ 0.2997.24bio-rad laboratories has higher revenue and earnings than surmodics . surmodics is trading at a lower price-to-earnings ratio than bio-rad laboratories , indicating that it is currently the more affordable of the two stocks . analyst ratingsthis is a summary of current ratings and target prices for bio-rad laboratories and surmodics , as reported by marketbeat . ",
        "com . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scorebio-rad laboratories00303.00surmodics00203.00bio-rad laboratories currently has a consensus price target of $ 273.33 , suggesting a potential upside of 9.13 % . surmodics has a consensus price target of $ 40.00 , suggesting a potential upside of 41.84 % . given surmodics ' higher possible upside , analysts plainly believe surmodics is more favorable than bio-rad laboratories . profitabilitythis table compares bio-rad laboratories and surmodics ' net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetsbio-rad laboratories1 .15 % 3.44 % 2.34 % surmodics5 .37 % 6.18 % 5.11 % risk and volatilitybio-rad laboratories has a beta of 0.97 , meaning that its share price is 3 % less volatile than the s&p 500 . ",
        "comparatively , surmodics has a beta of 0.85 , meaning that its share price is 15 % less volatile than the s&p 500.summarybio-rad laboratories beats surmodics on 7 of the 13 factors compared between the two stocks . about bio-rad laboratoriesbio-rad laboratories , inc. . is a manufacturer and distributor of its life science research and clinical diagnostics products . the company operates through two segments : life science and clinical diagnostics . it manufactures and supplies the life science research , healthcare , analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify , analyze and purify their components . ",
        "the life science segment develops , manufactures , sells and services reagents , apparatus and instruments used for biological research . the clinical diagnostics segment develops , manufactures , sells and services automated test systems , informatics systems , test kits and specialized quality controls for the healthcare market . as of december 31 , 2016 , bio-rad sold more than 8,000 products and services to a client base , including scientific research , healthcare , education and government customers around the world . about surmodicssurmodics , inc. . is a provider of medical device and in vitro diagnostic technologies to the healthcare industry . ",
        "the company operates through two segments : medical device and in vitro diagnostics . the company 's medical device segment consists of surface modification coating technologies to improve access , deliverability and predictable deployment of medical devices ; international cardiology and peripheral balloon design , development and manufacturing , as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device . the company 's in vitro diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests . the in vitro diagnostics segment manufactures and sells surface coatings to the diagnostic , biomedical research and life science markets . ",
        "in vitro diagnostics segment offers protein stabilization reagents , substrates , antigens and surface coatings . receive news & ratings for bio-rad laboratories daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for bio-rad laboratories and related companies with marketbeat . com 's free daily email newsletter .   "
    ]
}